Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of BPC-157 (PCO-02) in Healthy Volunteers
NCT02637284Phase 1Unknown
- Sponsor
- PharmaCotherapia
- Start
- Oct 2015
- Primary completion
- Feb 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bpc-157 in inflammatory bowel disease (IBD) (8 arms), sponsored by PharmaCotherapia. Primary endpoint: Adverse events at 6 months. Status: unknown.
02
Drugs
bpc-157
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02637284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637284.